drugset / Trial / NCT00274261

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

NCT00274261

RandomizedParallel-groupTriple-blindPrevention

Summary

This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. In addition, there is an opportunity for subjects to continue with study treatment for up to twelve months (365 days) and twelve cycles of treatment upon completion of the first six months of treatment.

Timeline

Start
2004-06
Primary completion
2008-07
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject C31G Unknown 35 mg Other
Comparator nonoxynol-9 (N-9) Unknown 100 mg Other

Indications